ALPS Medical Breakthroughs ETF (SBIO): ETF
ETF traded on ARCX under symbol SBIO. Quoted in usd.
ALPS Medical Breakthroughs ETF
-3.17%$53.87
ARCX:SBIOEquity
AUM $186.27M·YTD --·Yield --
About SBIO
The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.
Largest holdings
- ORKA Oruka Therapeutics Inc.4.58%
- CGON CG oncology Inc.4.33%
- MANE VeraDermics Inc.3.56%
- DNTH Dianthus Therapeutics Inc.3.37%
- EWTX Edgewise Therapeutics Inc.3.27%
- TVTX Travere Therapeutics Inc.3.13%
- DFTX Definium Therapeutics Inc.2.83%
- RLAY Relay Therapeutics Inc.2.61%
- XENE Xenon Pharmaceuticals Inc.2.58%
- AMLX Amylyx Pharmaceuticals Inc.2.50%
Dividend History
Benchmark Comparison
Compared against
Performance Returns
Drawdown Chart
Analyst Coverage
Savings Plan Calculator
Total Invested
$70,000
Final Portfolio
$110,086
Total Return
+$40,086
(+57.3%)
Dividends Reinvested
$0
compounded into portfolio
Defaults are seeded from historical performance and trailing twelve-month yield. Past performance is not a forecast. Feel free to adjust any input to model your own assumptions.
ETF Key Metrics
AUM$186.27M
NAV$55.60
Premium/Discount-3.11%
Expense Ratio0.50%
Market Cap$242.95M
Shares Outstanding3.60M
Inception DateDec. 30, 2014
Fund Details
IssuerALPS Funds
Asset ClassEquity
Beta0.95
SectorFinancial Services
DomicileUS
Websitealpsfunds.com/etfs/sbio
52-Week Range
$44.80$70.85
Current: $53.87
Volume
Volume18.35K
Avg Volume37.51K
Vol/Avg0.49x
30d
25.24K
60d
34.76K
90d
35.84K
Comparable ETFs